sangivamycin

05/01/2006 - "The purpose of the present study was to investigate the mechanisms involved in the antiproliferative and apoptotic effects of MCS-C2, a novel analog of the pyrrolo[2,3-d]pyrimidine nucleoside toyocamycin and sangivamycin, in human prostate cancer LNCaP cells. "

06/08/2005 - "The purpose of the present study was to investigate the anti-proliferative and apoptotic effects of MCS-C2, a novel synthetic analogue of the pyrrolo[2,3-d]pyrimidine nucleoside toyocamycin and sangivamycin, in human promyelocytic leukemia (HL-60) cells. "

02/20/2009 - "Furthermore, functional overlap between ARC and sangivamycin suggests that development of ARC may benefit from a retrospective of previous sangivamycin clinical trials. "
02/20/2009 - "ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC."
02/20/2009 - "Results demonstrated that sangivamycin, an extensively characterized pro-apoptotic nucleoside isolated from Streptomyces, had identical activity to ARC in terms of 1) cytotoxicity assays, 2) ability to induce a G2/M block, 3) inhibitory effects on RNA/DNA/protein synthesis, 4) transcriptomic response to treatment, 5) inhibition of protein kinase C, 6) inhibition of positive transcription elongation factor b (P-TEFb), 7) inhibition of VEGF secretion, and 8) activity within hollow fiber assays. "

11/12/2019 - "In orthotopically implanted tumors in mice, Sangivamycin was efficient in decreasing the growth of established tumors. "
02/07/2014 - "Our data thus indicate that sangivamycin may find clinical utility as a novel anti-cancer agent targeting PEL. "
11/01/2007 - "After the mice were administered with sangivamycin, tumor-induced angiogenesis was observed under the microscope. "
05/18/2007 - "Sangivamycin has shown a potent antiproliferative activity against a variety of human cancers. "
09/01/2014 - "Type-specific inhibition of cancer cell proliferation was observed at micromolar concentrations with the 4-N-(4-nitrobenzyl) derivatives of sangivamycin and toyocamycin, and also with 4-N-benzyltubercidin. "

11/01/1981 - "Cytokinetic and biochemical effects of sangivamycin in human colon carcinoma cells in culture."
11/01/1983 - "In vitro translational activity of messenger RNA following treatment of human colon carcinoma cells with sangivamycin."
03/01/1985 - "Comparison of the cellular and RNA-dependent effects of sangivamycin and toyocamycin in human colon carcinoma cells."
03/01/1985 - "The effects of the pyrrolopyrimidine antibiotics sangivamycin and toyocamycin on the synthesis of RNA and protein, ribosomal RNA processing, and cell viability were examined in colon carcinoma cell line HT-29. "
02/01/1985 - "The effects of six nucleoside and base analogs, 5-fluorouracil, 5-azacytidine, sangivamycin, toyocamycin, 8-azaguanine, and tubercidin, on ribosomal RNA processing and cell viability were examined in the colon carcinoma cell line HT-29. "